UT-TRACER
28.2.2023 15:02:03 CET | Business Wire | Press release
Tracer, the leader in brand protection and brand success, today announced the acquisition of Mad Power Technologies, a firm that provides AI and machine learning services with expertise in data capture and modeling, data engineering and advanced analytics, and cloud-based application delivery. Located in Madeira, Portugal, Mad Power Technologies will be the global Center of Excellence for Tracer AI and Data Science, extend Tracer’s European expansion, and accelerate customer support across Europe.
“Digital scamming, brand misuse and phishing have become increasingly pervasive across all geographies, as sophisticated networks of bad actors seek to take advantage of businesses and their customers through online fraud and brand infringement,” said Rick Farnell, CEO of Tracer. “The acquisition of Mad Power Technologies provides a team of seasoned AI experts, developers and analysts to accelerate our pace of innovation and expansion into EMEA markets. Customers of all sizes across the globe are telling us that legacy brand protection offerings lack innovation and aren't keeping up with the needs of their business. With our modern human-in-the-loop (HITL) AI approach, we are innovating to meet the current and future needs of the global market and delivering world class business outcomes for the time to trace (TTT), time to recommend (TTR) and time to take down (TTTD) instances of online brand misuse. We will continue to invest in our Tracer platform as we set the standard for brand success.”
Tracer to Establish Center of Excellence for AI and Data Science
With the Mad Power acquisition, Tracer has established a Center of Excellence (CoE) for AI and Data Science in Madeira, Portugal, to continue developing talent in AI and software development. The CoE for AI and Data Science will accelerate Tracer’s product innovation for HITL AI and machine learning including computer vision, natural language processing and sentiment analysis. Tracer will also establish its global Academy Training Program in Portugal, which will enable the company to train technology talent in the fields of AI, data science and software engineering. Since the launch of the partnership between Mad Power and Tracer, the CoE has onboarded 60 new employees dedicated to technology innovation.
The CoE for AI and Data Science will accelerate Tracer’s ability to process and analyze massive volumes of data across digital channels to prevent brand misuse, uncover market insights and accelerate brand success. Across traditional Web2 and emerging Web3 channels, brands today face a growing number of sophisticated digital threats. Failure to identify and mitigate risks quickly can lead to copyright and trademark infringements, brand impersonation, digital counterfeiting and other types of brand misuse.
The company’s flagship product, Tracer Protect, is the first-of-its-kind SaaS platform that leverages HITL AI and machine learning to continuously trace, analyze and mitigate brand misuse across global Web2 and Web3 channels. By incorporating human judgment at key decision points, the Tracer Platform enables continuous improvement to the platform’s AI and machine learning models and algorithms.
To learn more, visit the website or build your customized Tracer Analysis and brand misuse report.
Additional Resources
About Tracer
Tracer accelerates Brand Success for the world’s most-loved brands, including four of the top five most valuable global businesses. In today’s landscape of highly sophisticated digital threats and hyper-competition, the stakes have never been higher for businesses to identify risks and opportunities across the evolving digital universe. The Tracer Platform mitigates digital brand misuse to preserve authentic customer interactions and uncovers new categories of dynamic market insights to fuel better business decisions. TracerAI™ technology continuously captures and filters data from thousands of global Web2 and Web3 digital sources, including domains and websites, marketplaces, social media, mobile apps and app stores, search engines, NFT marketplaces, metaverse environments, Web3 domains and more. TracerAI applies a suite of advanced, human-in-the-loop AI and machine learning approaches to analyze and correlate instances of brand use and misuse across this digital landscape. This allows businesses to “see the unseen” and control the use of their brand online, improving brand integrity to increase customer loyalty and satisfaction. The platform’s market-leading Tracer Protect product for online brand protection provides real-time monitoring and analysis of IP and copyright infringement, fraud, brand impersonation, digital and digital-plus-physical counterfeiting and other forms of brand misuse. This enables businesses to prevent brand misuse before it has a chance to damage their brands. For the highest level of security for valuable domains, Tracer Registrar provides enterprise-grade corporate domain registration and management so businesses can protect their brand for the long-term from the start. Built on more than a decade of real-world brand protection experience, the Tracer Platform yields rapid infringement detection with market-leading accuracy, leading to vastly faster time to detection and enforcement.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005572/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom